Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 21,412 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Phase II Clear all
Active, not recruiting Phase 2 Interventional

Daratumumab to Treat Active Lupus Nephritis

NCT04868838
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Daratumumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Nov 15, 2026, 2:42 PM EST
Recruiting Phase 2 Interventional

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

NCT07527858
View directory record Official record
Conditions
Advanced Microsatellite Stable Colorectal Cancer
Interventions
Denikitug, Nivolumab, Bevacizumab, Trifluridine-Tipiracil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
North Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 15, 2026, 2:42 PM EST
Completed Phase 1Phase 2 Interventional Results available

Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor

NCT00711243
View directory record Official record
Conditions
Gastric Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel, fluorouracil, oxaliplatin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Nov 15, 2026, 2:42 PM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine

NCT05679908
View directory record Official record
Conditions
Chronic Migraine, Chronic Migraine, Headache, Chronic Migraine Without Aura, Aura Migraine
Interventions
TNX-1900, Placebo Nasal Spray
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
26
States / cities
Little Rock, Arkansas • Lemon Grove, California • Oceanside, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Nov 15, 2026, 2:42 PM EST
Terminated No phase listed Interventional Results available

Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17

NCT03462576
View directory record Official record
Conditions
Decompensated Cirrhosis
Interventions
Methacetin Breath Test, Emricasan, Placebo oral capsule
Combination Product · Drug
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lakewood Rch, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Nov 15, 2026, 2:42 PM EST
Completed Phase 2 Interventional

Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer

NCT00006017
View directory record Official record
Conditions
Lung Cancer
Interventions
becatecarin
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
2
States / cities
Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Nov 15, 2026, 2:42 PM EST
Completed Phase 2 Interventional

Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission

NCT00005940
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions
iodine I 131 monoclonal antibody BC8, busulfan, cyclophosphamide, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, cyclosporine, methotrexate, laboratory biomarker analysis
Radiation · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
16 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
3
States / cities
Richland, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Nov 15, 2026, 2:42 PM EST
Completed Phase 2 Interventional

A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections

NCT00303589
View directory record Official record
Conditions
Soft Tissue Infections
Interventions
Standard care, beta-lactam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
8
States / cities
Birmingham, Alabama • Mobile, Alabama • Melbourne, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 15, 2026, 2:42 PM EST
Completed Phase 1Phase 2 Interventional

YSPSL for Prevention of Delayed Graft Function Part B

NCT00298168
View directory record Official record
Conditions
Kidney Diseases
Interventions
YSPSL, placebo
Drug
Lead sponsor
Y's Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Nov 15, 2026, 2:42 PM EST
Completed Phase 2 Interventional

Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer

NCT00003968
View directory record Official record
Conditions
Kidney Cancer
Interventions
bryostatin 1
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
17
States / cities
Flemington, New Jersey • Lakewood, New Jersey • Millville, New Jersey + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Nov 15, 2026, 2:42 PM EST
Active, not recruiting Phase 2 Interventional

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

NCT04462406
View directory record Official record
Conditions
Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma
Interventions
Ipilimumab, Nivolumab, Patient Observation, Pembrolizumab
Biological · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
482
States / cities
Fairhope, Alabama • Mobile, Alabama • Fairbanks, Alaska + 330 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 15, 2026, 2:42 PM EST
Completed Phase 2 Interventional

A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

NCT05963984
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
Interventions
Samuraciclib, Fulvestrant
Drug
Lead sponsor
Carrick Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Ocala, Florida • Baltimore, Maryland • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Nov 15, 2026, 2:42 PM EST
Terminated Not applicable Interventional Results available

Standard Pain Control or Intrathecal Therapy in Controlling Pain in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

NCT00660348
View directory record Official record
Conditions
Pain, Pancreatic Cancer
Interventions
morphine sulfate, Medtronic intrathecal pump
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Nov 15, 2026, 2:42 PM EST
Completed Phase 2 Interventional Results available

Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.

NCT04304508
View directory record Official record
Conditions
Acute Non-cardioembolic Ischemic Stroke
Interventions
BAY2433334, BAY2433334 matching placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
45 Years and older
Enrollment
1,808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Tampa, Florida • Golden Valley, Minnesota • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Nov 15, 2026, 2:42 PM EST
Withdrawn Phase 2 Interventional

A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma

NCT02402725
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Nov 15, 2026, 2:42 PM EST
Not yet recruiting Phase 2 Interventional

A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation

NCT07814417
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Olomorasib, Cetuximab, Oxaliplatin, Leucovorin/levofolinate calcium, 5-fluorouracil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 15, 2026, 2:42 PM EST
Completed Phase 2 Interventional Results available

Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women

NCT00256217
View directory record Official record
Conditions
DCIS
Interventions
Anastrozole
Drug
Lead sponsor
Rita Sanghvi, Mehta
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Nov 15, 2026, 2:42 PM EST
Completed Not applicable Interventional

Celiac Plexus Radio-Surgery for Pain Management

NCT03323489
View directory record Official record
Conditions
Advanced Cancer, Pancreas Cancer, Pain
Interventions
Celiac Plexus Radiosurgery
Radiation
Lead sponsor
Dr. Yaacov Lawrence
Government
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Nov 15, 2026, 2:42 PM EST
Recruiting Phase 2 Interventional

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

NCT05113368
View directory record Official record
Conditions
Ovarian Cancer, Serous Ovarian Cancer
Interventions
Regorafenib, Fulvestrant
Drug
Lead sponsor
Sarah K. Lynam MD
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Nov 15, 2026, 2:42 PM EST
Active, not recruiting Phase 2 Interventional Results available

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

NCT04619004
View directory record Official record
Conditions
Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Interventions
Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
33
States / cities
Gilbert, Arizona • Duarte, California • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 15, 2026, 2:42 PM EST
Recruiting Phase 2 Interventional

Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas

NCT02598349
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Proton Radiation, Capecitabine, Surgical resection
Radiation · Drug · Procedure
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2040
U.S. locations
4
States / cities
Little Rock, Arkansas • Jacksonville, Florida • Warrenville, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Nov 15, 2026, 2:42 PM EST
Not listed Phase 2 Interventional

A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19

NCT04780685
View directory record Official record
Conditions
Covid19
Interventions
hMSC
Biological
Lead sponsor
Stemedica Cell Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Fullerton, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Nov 15, 2026, 2:42 PM EST
Recruiting Not applicable Interventional

MenoZen VR for Menopause Symptom Management

NCT07633743
View directory record Official record
Conditions
Menopause
Interventions
MenoZen
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 15, 2026, 2:42 PM EST
Completed Not applicable Interventional

Optical Spectroscopy in Evaluating Tumor Margins in Patients Who Have Undergone Surgery for Breast Tumors

NCT00625417
View directory record Official record
Conditions
Breast Cancer
Interventions
breast biopsy, histopathologic examination, light-scattering spectroscopy, therapeutic conventional surgery
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 99 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Nov 15, 2026, 2:42 PM EST